A NEW ERA OF VACCINES

The Novavax COVID-19 Vaccine, Adjuvanted is now available in
the U.S. under Emergency Use Authorization for primary vaccination
for individuals 12+, and as a first booster dose for adults

See conditions of use

CDC Vaccine Finder

Latest press release on vaccine candidates

View press releases

COVID-19 vaccine research updates

Novavax COVID-19 vaccine (recombinant, adjuvanted) is now conditionally authorized in several regions

Latest update

2 billion

doses per year
at full capacity

10+ years

of nanoparticle
vaccine development

1,500+

employees
worldwide

areas of
research

Novavax information for:

General public

Medical professionals

Investors

Career seekers

Novavax information for:

NEWS & MEDIA

Novavax Announces Launch of Global Vaccine Education Programs

We focus on this so you can focus on that

Full press release

NEWS & MEDIA

Current Protocol for Phase 3 Clinical Trial of NVX-CoV2373 in the U.S. and Mexico

Full press release

Novavax first quarter 2022 financial results

Browse the calendar and sign up to view investor-related events and announcements. Webcasts and presentations that have been archived are also available by viewing historical event details.